Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$11.7MCash on Hand
4.9mo Cash Runway
Follow OGI by emailGet an email when OGI reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about OGI, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 16, 2026 ·
Listing Nasdaq notified Organigram on November 11, 2026 that its common shares fell below the US$1.00 minimum bid for 30 consecutive business days. The company has until May 10, 2027 to regain compliance. The notice does not affect TSX listing. Form 6-K · SEC filing · Press release
Nov 13, 2026 ·
Deal Organigram agreed to acquire Aurora Cannabis under a plan of arrangement valued at about C$561 million, offering C$7.80 per share in cash or 5.8626 Organigram shares, with C$25.2 million and C$38.4 million termination fees. BAT will buy shares for C$187.5 million in a private placement. Form 6-K · SEC filing · Press release
Nov 3, 2026 ·
Deal Organigram will acquire Aurora for C$7.80 per share in cash, Organigram shares or a combination, valuing Aurora at about C$561 million on a fully diluted basis. The price is a 93% premium to Aurora's unaffected price and 21% above the Curaleaf hostile bid. Form 6-K · SEC filing · Press release
Oct 15, 2026 ·
Restructuring Organigram expects annualized run-rate cost savings of $8 million to $10 million from integrating Sanity Group and a unified global operating model, with $5 million to $6 million in fiscal 2027 and $2 million in one-time integration costs. The company also plans to discontinue three brands and trim its SKU assortment. Form 6-K · SEC filing · Press release
Sep 30, 2026 ·
Organigram will premiere its 2026 OG Investor Session today at 4:00 p.m. ET on X, with simulcasts on LinkedIn and YouTube. Presentations from CEO James Yamanaka, CFO Greg Guyatt and Finn Age Hänsel, followed by a fireside Q&A. Form 6-K · SEC filing · Press release
Sep 3, 2026 ·
Organigram announced details of its 2026 OG Investor Session, a video presentation premiering September 30 at 4:00 p.m. ET featuring CEO James Yamanaka, CFO Greg Guyatt and Finn Age Hänsel, with registration open at www.organigram.ca/investor-day-2026 and investor-submitted questions for a fireside chat. Form 6-K · SEC filing · Press release
Sep 1, 2026 ·
Deal Organigram amended its Sanity Group GmbH purchase agreement, fixing the earnout at 85% of the maximum: €20 million in cash plus about €76 million in shares, payable after April 1, 2027. The company also appointed Finn Age Hänsel and Adrian Frenzel to leadership roles. Form 6-K · SEC filing · Press release
Aug 20, 2026 ·
Deal Organigram accelerated integration of Sanity Group, appointing Finn Age Hänsel as President, Rest of World & Chief Strategy Officer and Adrian Frenzel as Global COO. The Sanity earnout was amended to a fixed 85% of the maximum, payable €20 million in cash plus about €76 million in shares from April 1, 2027. Form 6-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
💰 Cash Runway & Dilution Risk
OGI holds $11.7M in cash and short-term investments and burns about $7.1M/quarter from operations,
an estimated runway of 4.9 months at that rate (BioRadar estimate, not company guidance).
Share count 108,585,492 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full OGI picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for OGI and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.